Table of Contents

Red cell disorders: initial evaluation of anaemia; microcytic anaemia; normocytic anaemia; macrocytic anaemia; pancytopenia; anaemia in the neonate; neonatal anaemia due to impaired RBC production; hemolytic aenemia; hemoglobinuria; presumed iron deficiency anaemia which fails to respond to oral iron; thalassemia; newborn screening for hemoglobinopathies; sickle cell anaemia with fever; management of painful vaso-occlusive episodes in sickle cell disease; evaluation and management of anemia in sickle cell disease; polycythemia (erythrocytosis); red cell transfusion. White cell disorders: leukocytosis; eosinophilia; neutropenia; the child with recurrent infection - leukocyte dysfunction. Reticuloendothelial disorders: llymphadenopathy - generalized lymphadenopathy; lymphadenopathy - localized adenopathy; splenomegaly. Coagulation disorders: evaluation of a child with bleeding or abnormal coagulation screening tests; evaluation of a child with thrombocytopenia; thrombocytopenia in the well neonate; thrombocytopenia in the ill neonate; platelet dysfunction; thrombocytosis; treatment of bleeding in children with hemophilia; evaluation of a child with hemophilia who fails infusion therapy; consumptive coagulopathy; thrombophilia evaluation in a newborn infant with thrombosis; thrombophilia evaluation in a child with thrombosis. Malignant disorders: assessment of a child with suspected leukaemia; assessment of a mediastinal mass; assessment of an abdominal mass; assessment of a pelvic mass; assessment of a soft tissue mass; assessment of bone lesions; initial management of a child with a newly diagnosed brain tumor; supratentorial brain tumors; brain tumors of the posterior fossa, brain stem and visual pathway; initial management of a child with a tumor involving or near the spinal cord; recognition and management of tumor lysis syndrome; recognition and management of superior vena cava syndrome; febrile neutropenia; management of biopsy tissue in children with possible malignancies; diagnosis and management of pulmonary infiltrates during chemotherapy; monitoring for late effects in children with malignancies; useful normal laboratory values.